Contact Information: Website: www.TaraMinerals.com Francis Biscan Jr. Phone: (630) 462-2079
Tara Minerals Announces Additional Results From New Vein - 919 g/t Silver, 29.65% Zinc, and 14.1% Lead
| Source: Tara Minerals Corp.
CHICAGO, IL--(Marketwire - January 26, 2010) - Tara Minerals Corp. (OTCBB : TARM ) (BERLIN : 6T3 ), a subsidiary of Tara Gold Resources Corp. (PINKSHEETS : TRGD )
(FRANKFURT : T8N ), is pleased to announce additional results from the new
Silver, Zinc, and Lead vein discovery at its flagship Don Roman mine in
Mexico. Channel samples across an additional 2 meters of the exposed
portion of the vein returned 919 grams per tonne Silver, 29.65% Zinc, and
14.1% Lead.
To date, more than 8 meters of the vein width has been exposed (see news
release dated January 21, 2010) with work ongoing to identify the hanging
wall and footwall edges. Tara Minerals continues to drift towards the new
vein structure from existing mine tunnels with the goal of adding this
material into the current mining plan.
Mr. Francis Biscan Jr., President of Tara Minerals Corp., stated, "Results
to date are extremely encouraging and efforts to identify the hanging wall
and footwall edges are continuing. Results of these ongoing efforts will be
announced at the appropriate time."
About Tara Minerals Corp.
Tara Minerals Corp. is generating cash from the sale of Silver, Zinc, and
Lead concentrate from its producing Don Roman mine and mill, located in
Choix, Mexico. Management is focused on creating long-term shareholder
value as this capital is deployed to increase throughput, enhance
resources, further outline new discoveries/targets, and acquire additional
strategic assets. Tara's strength in recognizing value early and strategy
of reducing risk through a foundation of cash flow, positions it for
low-risk value creation.
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: The statements contained herein which are not historical are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed in the
forward-looking statements, including, but not limited to, certain delays
beyond the company's control with respect to market acceptance of new
technologies or products, delays in testing and evaluation of products, and
other risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission.